The authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

The authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

6. Altorki NK, Yip R, Hanaoka T, Bauer T, Aye R, Kohman L, et al; I-ELCAP Investigators. Sublobar resection is equivalent to lobectomy for clinical stage IA lung cancer in solid nodules. *J Thorac Cardiovasc Surg*. 2014;147:754-62.

<https://doi.org/10.1016/j.jtcvs.2020.04.009>

REPLY: THE IMPORTANCE OF APPROPRIATE SELECTION FOR SEGMENTECTOMY

Reply to the Editor:

We appreciate the response to our commentary by Liu and colleagues¹ regarding the study by Razi and colleagues² evaluating segmentectomy versus lobectomy for cT1 N0 M0 non-small cell lung cancer who were discovered to have “unsuspected” pathologic N1 or N2 disease. We largely agree with the key points raised by Liu and colleagues. Appropriate selection of patients for segmentectomy is critical. In general, segmentectomy can be a reasonable choice for small, peripheral tumors that are ≤ 2 cm in diameter when a segmental margin that is greater than or equal to the tumor diameter is achievable, particularly in patients with advanced age, who are frailer and have reduced cardiopulmonary reserve. There are 2 ongoing randomized controlled trials—the results of which are eagerly anticipated—designed to further improve our understanding of patient selection for limited resection for cT1a (peripheral tumors < 2 cm) N0 M0 non-small cell lung cancer: CALGB 140503³ and JCOG0802/WJOG4607L.⁴

In the era of lung cancer screening and increased identification of small, peripheral tumors, the uncommon scenario of unsuspected N1 and N2 disease during a segmentectomy will likely become more frequent. It will be important to continue evaluating questions regarding the extent of parenchymal resection in the setting of N1 and unsuspected N2 disease in well-designed multicenter studies that have granular data that include details about N1 and N2 lymph nodes and that have data regarding pulmonary function.

Chi-Fu Jeffrey Yang, MD
Mark F. Berry, MD
Department of Cardiothoracic Surgery
Stanford University Medical Center
Stanford, Calif

References

1. Liu C, Tian D, Pu Q. Do not go too far when choosing intentional segmentectomy for small-sized lung cancers. *J Thorac Cardiovasc Surg*. 2020;160:e85-6.
2. Razi S, Nguyen D, Villamizar N. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease. *J Thorac Cardiovasc Surg*. 2020;159:2469-83.
3. Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). *Lancet Respir Med*. 2018;6:915-24.
4. Suzuki K, Saji H, Aokage K, Watanabe S-I, Okada M, Mizusawa J, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial. *J Thorac Cardiovasc Surg*. 2019;158:895-907.

<https://doi.org/10.1016/j.jtcvs.2020.03.146>

ROBOTIC SEGMENTECTOMY: WE ARE STILL ON THE WAY To the Editor:

In their Commentary, Song and Flores¹ propose several thoughtful questions and describe certain limitations of robotic segmentectomy. We cannot agree with them more. However, we are still willing to clarify the question inherent to their Commentary.

Our study² indicated that robot-assisted thoracic surgery (RATS) demonstrated improved N1 node retrieval as a potential benefit; however, nodal upstaging did not achieve a significant difference between the 2 groups. We only observed 2 cT1b N0 adenocarcinomas in the RATS group upstaged to pT1b N2 after propensity score-matched analysis.² The possible reasons for this low rate of nodal upstaging in our study were the careful determination of clinical stage with positron-emission tomography, computed tomography, and other methods as well as strict selection of slowly growing ground glass opacity (GGO) nodules for segmentectomy procedures in both cohorts. It seems that difference in nodal upstaging between these 2 techniques is still controversial. Wilson and colleagues³ reported that the rate of nodal upstaging for robotic anatomical resection, including lobectomy and segmentectomy, appeared to be superior to video-assisted thoracoscopic surgery (VATS) and similar to thoracotomy for stage I non-small cell lung cancer. Further, a recent